一种非侵入性的慢性乙型肝炎患者纤维化测试其他非专利分

StephenW

Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores


Despite the availability of patented non-invasive methods, evaluation of the degrees of liver fibrosis remains difficult when conducting a retrospective study. Such inadequacy is largely caused by requirement of biochemical parameters rarely performed in routine clinical tests.

We developed a novel fibrosis HB-F score using commonly performed tests for HBV infected patients.

Methods: 424 patients with chronic HBV infection were included. Using clinical and virological data, HB-F score was developed from a training cohort (n = 213) and validated in a separate cohort (n = 211).

The performance was compared with five other unpatented scores using ROC curves.

Results: Univariate and multivariate analysis revealed that age, AST/ALT ratio, platelet count and prothrombin time prolongation were significantly associated with the ISHAK fibrosis score, and were used to calculate the HB-F score. When HB-F was used to assess prominent fibrosis and cirrhosis, the AUC was 0.81 and 0.80 respectively in the training cohort, and 0.80 and 0.76 respectively in the validation cohort.

HB-F had the highest AUC compared with other scores. Furthermore, in assessing paired liver biopsies with increase or decrease of ISHAK scores, HB-F showed significant change in the same direction.

Conclusions: A new non-invasive score was developed, which could be used to assess severity of liver fibrosis in retrospective longitudinal studies in HBV patients.

Author: Chao-Wei HsuKung-Hao LiangShiu-Feng HuangKuo-Chien TsaoChau-Ting Yeh
Credits/Source: BMC Research Notes 2013, 6:212

StephenW

尽管有专利的非侵入性的方法，进行了回顾性研究时，仍然难以评估肝纤维化程度。这种不足主要是由于很少在日常的临床试验进行生化指标的要求。

我们开发了一种新型的纤维化HB-F使用通常进行的测试，测试的得分为HBV感染的患者。

方法：424例慢性HBV感染者都包括在内。使用临床和病毒学数据从训练队列，HB-F比分是在一个单独的队列组（n =211）（N= 213）和验证。

性能比较采用ROC曲线与其他五个非专利分数。

结果：单因素和多因素分析显示，年龄，AST/ ALT比值，血小板计数，凝血酶原时间延长，Ishak纤维化评分显着相关，被用来计算HB-F得分。当HB-F是用来评估突出纤维化，肝硬化，药时曲线下面积（AUC），分别为0.81和0.80，分别在训练队列，和0.80和0.76，在验证队列。

HB-F与其他得分最高的AUC相比。此外，在HB-F评估配对肝活检伊沙克分数的增加或减少，在相同的方向上表现出显着的变化。

结论：开发一种新的非侵入性的得分，它可以用来追溯乙肝患者的纵向研究来评估肝纤维化程度。

作者：伟超HsuKung豪峰LiangShiu HuangKuo建叶TsaoChau婷
币/来源：BMC研究附注2013年，6:212

MP4

作者单位?

StephenW

回复 MP4 的帖子

Chao-Wei Hsu
1,†
Email: [email protected]
Kung-Hao Liang
1,†
Email: [email protected]
Shiu-Feng Huang
2
Email: [email protected]
Kuo-Chien Tsao
3,4
Email: [email protected]
Chau-Ting Yeh
1*
*
Corresponding author
Email: [email protected]
1
Liver Research Center, Chang Gung Memorial Hospital, 199, Tung Hwa North
Road, Taipei, Taiwan
2
Department of Pathology, Chang-Gung Memorial Hospital, Taoyuan, Taiwan
3
Department of Medical Biotechnology and Laboratory Science, Research Cente
r
for Emerging Viral Infections, Chang Gung University, Taoyuan, Taiwan
4
Departments of Laboratory Medicine, Chang Gung Memorial Hospital,
Taoyuan,, Taiwan
†
Equal contributors.

下载论文:http://www.biomedcentral.com/content/pdf/1756-0500-6-212.pdf